Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 2Sarcoma, Alveolar Soft Part 1Recurrence 1Colonic Neoplasms 1

Interventions

Peripheral Blood Stem Cell Transplantation 5fludarabine phosphate 4Radiotherapy 4Antilymphocyte Serum 4Vincristine 3Vinblastine 3Procarbazine 3Prednisolone 3Methylprednisolone 3Melphalan 3Filgrastim 3Doxorubicin 3Cyclophosphamide 3Chlorambucil 3Busulfan 3Bortezomib 3Bevacizumab 3tipifarnib 2Vorinostat 2Sorafenib 2Oxaliplatin 2Mycophenolic Acid 2Methotrexate 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Dacarbazine 2Cyclosporine 2Bleomycin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Recurrence × atropine sulfate-diphenoxylate hydrochloride drug combination × Clear all
NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡